+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Thalassemia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 120 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4987272
UP TO OFF until Dec 31st 2023

The thalassemia treatment market studied was projected to grow with a CAGR of nearly 7.6% over the forecast period. The major factors attributing to the growth of the market are increasing prevalence of thalassemia and also growing awareness to treat thalassemia. According to National Center on Birth Defects and Developmental Disabilities, thalassemia, affects at least 1,000 people in the United States. Furthermore the growing investements in research and development programs by the biotechnology and pharmaceutical companies boosting the market growth. Chelation therapy and blood transfusion are the conventional treatments for thalassemia patients, as these are cost effective and are easily available compared to bone marrow transplantation. Chelation therapy uses drugs such as deferasirox for the treatment of chronic iron overload occurs during multiple blood transfusions among non-transfusion-dependent thalassemia patients. Chelation therapy drugs used subcutaneous or intravenous with slow infusion method for purifying blood, raise the possibility of curing thalassemia in patients. However the high cost of the treatment is major drawback for the market growth.

Key Market Trends

Chelation Therapy segment is expected to be the Fastest Growing Segment

  • Iron overload is the main cause of sickness for thalassemia patients. Even non- transfused patients develop iron overload secondary to boosted intestinal absorption of dietary iron. Iron overload is a leading cause of mortality and organ injury. The only treatment options for removing excess iron are phlebotomy and chelation. While phlebotomy is a very effective way of removing iron, it is not appropriate for patients with thalassemia except after bone marrow transplantation.
  • The segment is projected to expand at an exponential growth rate during the forecast period. The major factors driving the growth of the segment are increasing incidence of thalassemia patients and increasing research and development investments.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall thalassemia treatment market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of thalassemia patients in the region and established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and increase in number of research partnerships are some of the drivers expected to increase the market growth. The United States has the main share due to the rising awareness about the condition and increasing number of populations with thalassemia carrier gene, and growth in birth rates due to variation of genes among the population.

Competitive Landscape

The thalassemia treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market Bluebird Bio, IONIS Pharmaceuticals, Novartis AG, Bellicum Pharmaceuticals, ApoPharma Inc, SG Pharma Pvt. Lmt. Acceleron Pharma, Inc., and Kiadis Pharma, Lonza Group Ltd.,

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Thalassemia
4.2.2 Increasing Awareness of Thalassemia Treatment
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Treatment Type
5.1.1 Blood Transfusions
5.1.2 Iron Chelation Therapy
5.1.3 Folic Acid Supplements
5.1.4 Others
5.2 By Disease Type
5.2.1 Alpha Thalassemia
5.2.2 Beta Thalassemia
5.3 By End-User
5.3.1 Hospitals
5.3.2 Research Institutes
5.3.3 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Bluebird Bio
6.1.2 IONIS Pharmaceuticals
6.1.3 Novartis AG
6.1.4 Bellicum Pharmaceuticals
6.1.5 ApoPharma Inc
6.1.6 Pfizer, Inc.
6.1.7 Acceleron Pharma, Inc.
6.1.8 Kiadis Pharma
6.1.9 SG Phrma Pvt. Lmt.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Bluebird Bio
  • IONIS Pharmaceuticals
  • Novartis AG
  • Bellicum Pharmaceuticals
  • ApoPharma Inc
  • Pfizer, Inc.
  • Acceleron Pharma, Inc.
  • Kiadis Pharma
  • SG Phrma Pvt. Lmt.